RxDoctor Payments Data

Christine Hunt, MD

Dermatology · Pasadena, TXNPI 1366607194

Payments from drug & device makers

$28,854in general payments, 2019–2025

Across 1,240 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Johnson & Johnson$4K
  • Bristol Myers Squibb$3K
  • Novartis$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Incyte Corporation$1K
  • plus $12K from 33 others

What the payments were for

  • Consulting fees$1,7966%
  • Speaking & faculty fees$2,6009%
  • Travel & lodging$800%
  • Food & beverage$24,00783%
  • Education$3711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,854 in reported general payments places this provider in the 85th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$185,488
Medicare patients
522
Services billed
3,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa17$375,388
RinvoqUpadacitinib30$245,161
Dupixent PenDupilumab57$230,504
TremfyaGuselkumab15$207,256
OtezlaApremilast32$153,672
Dupixent SyringeDupilumab13$51,655
Clobetasol Propionate162$5,864
Fluorouracil63$4,678
Metronidazole88$4,196
Dutasteride97$3,860
Tacrolimus19$3,504
Ketoconazole134$2,039
Tretinoin21$1,943
Mometasone Furoate87$1,738
Doxycycline Hyclate90$1,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$3,982$245,16130 claims
Johnson & JohnsonTremfya$3,980$207,25615 claims
AmgenOtezla$1,251$153,67232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Pasadena

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →